Bronchogenic Carcinoma
📧 Sign up to get email alerts when something new happens for Bronchogenic Carcinoma.
Sign up freeTop drugs studied for this disease
-
EMA withdrawal · 2017-11-10EMA Application withdrawn: Kyomarc (bevacizumab) — Amgen Europe B.V.
The EMA withdrew the application for Kyomarc (bevacizumab) from Amgen Europe B.V., relating to several carcinomas and neoplasms.